Phase 3 Trial for Myotonic Dystrophy Agent AMO-02 To Begin Following FDA Meeting

Retrieved on: 2024-05-06 22:07:46

Tags for this article:

Clinical research

Design of experiments

Myotonic dystrophy

Clinical trial

Placebo-controlled study

Click the tags to see associated articles and topics

Phase 3 Trial for Myotonic Dystrophy Agent AMO-02 To Begin Following FDA Meeting. View article details on hiswai:

Excerpt

... Health, Johns Hopkins AITC and Harvard Innovation Labs. Neal is a “Top Healthcare Voice” on LinkedIn with a 35k+ following. Advertisement. Related ...

Article found on: www.neurologylive.com

View Original Article